---
figid: PMC7052940__jcav11p2000g002
figtitle: Resistance to FGF/FGFR inhibitors
organisms:
- Homo sapiens
- Mus musculus
- Oryzias latipes
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC7052940
filename: jcav11p2000g002.jpg
figlink: pmc/articles/PMC7052940/figure/F2/
number: F2
caption: Mechanism of resistance to FGF/FGFR inhibitors. (A) Gatekeeper mutation in
  the FGFR kinase domain often results in resistance to FGFR inhibitors. (B) FGFR
  inhibition can activate other membrane receptor signaling pathwayin the feedback
  way, like EGFR, ERBB3 or MET. The downstream cascades may be mediated by MAPK-ERK1/2,
  PI3K-AKT and GSK signaling pathway. (C) Loss of PTEN can increase the activation
  of PI3K-AKTsignaling pathway. (D) EMT can contribute to the resistance to FGFR inhibitors.
  (E) ABCG2 regulated drug-efflux can also contribute to the resistance to FGFR inhibitors.
  (F) RASA1 is a protein activator, which can promote the translation of activated
  RAS to inactivated RAS. The inactivation of RASA1 may induce the resistance to FGFR
  inhibitors.
papertitle: FGF/FGFR signaling pathway involved resistance in various cancer types.
reftext: Yangyang Zhou, et al. J Cancer. 2020;11(8):2000-2007.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8963636
figid_alias: PMC7052940__F2
figtype: Figure
redirect_from: /figures/PMC7052940__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7052940__jcav11p2000g002.html
  '@type': Dataset
  description: Mechanism of resistance to FGF/FGFR inhibitors. (A) Gatekeeper mutation
    in the FGFR kinase domain often results in resistance to FGFR inhibitors. (B)
    FGFR inhibition can activate other membrane receptor signaling pathwayin the feedback
    way, like EGFR, ERBB3 or MET. The downstream cascades may be mediated by MAPK-ERK1/2,
    PI3K-AKT and GSK signaling pathway. (C) Loss of PTEN can increase the activation
    of PI3K-AKTsignaling pathway. (D) EMT can contribute to the resistance to FGFR
    inhibitors. (E) ABCG2 regulated drug-efflux can also contribute to the resistance
    to FGFR inhibitors. (F) RASA1 is a protein activator, which can promote the translation
    of activated RAS to inactivated RAS. The inactivation of RASA1 may induce the
    resistance to FGFR inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Itk
  - Slc22a3
  - Erbb3
  - Pik3r1
  - Ephb2
  - Mapk1
  - Mapk3
  - Pten
  - Akt1
  - ras
  - Hras
  - Kras
  - Rem1
  - ITK
  - SLC22A3
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - ERBB3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - EPHB2
  - MAPK1
  - MAPK3
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - bnl
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - sgg
  - Erk7
  - rl
  - mid
  - Akt
  - Ras64B
  - Ras85D
---
